<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400387</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2006-001984-53</org_study_id>
    <nct_id>NCT00400387</nct_id>
  </id_info>
  <brief_title>Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss</brief_title>
  <official_title>Phase III Study Analyzing the Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <brief_summary>
    <textblock>
      With this clinical trial the investigators will analyze whether the rate of pregnancy losses&#xD;
      before the 24th week of gestation can be reduced by dalteparin treatment in habitual&#xD;
      aborters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent pregnancy loss (RPL) is a common health problem with three or more loses affecting&#xD;
      1-2% and two or more losses affecting up to 5% of women at the reproductive age (Brenner&#xD;
      2003).&#xD;
&#xD;
      Several aetiologies have been identified or are under discussion to play a role in RPL,&#xD;
      including chromosomal translocations and inversions, anatomic alterations of the uterus,&#xD;
      endocrinological abnormalities, autoimmune disorders infection, smoking and alcohol&#xD;
      consumption, exposure to environmental factors as well as coagulation and immunoregulatory&#xD;
      defects (Pandey 2005, Lee 2000). About 30-40% of cases of RPL remain unexplained after&#xD;
      standard gynaecological, hormonal and karyotype analysis (Rey 2000).&#xD;
&#xD;
      As stated by Pandey et al (Pandey 2005), a successful implantation during pregnancy requires&#xD;
      a balanced equilibrium between coagulation, fibrinolysis and vascular remodeling by the&#xD;
      process of angiogenesis in order to avoid excess fibrin accumulation in placental vessels and&#xD;
      intervillous spaces (Buchholz 2003). However, thrombosis in decidual vessels is reported to&#xD;
      be one of the major causes of RPL (Arias 1998) and could be explained by excessive thrombosis&#xD;
      of the placental vessels, placental infarction, and secondary uteroplacental insufficiency.&#xD;
&#xD;
      Recurrent pregnancy loss is a well-described complication of the antiphospholipid antibody&#xD;
      syndrome and is thought to be associated with thrombosis of placental vessels, often with&#xD;
      evidence for placental infarction. More recently, inherited thrombophilic abnormalities have&#xD;
      been linked to RPL and other obstetric complications. At least 16 case-control studies found&#xD;
      a high prevalence of factor V Leiden (FVL) in women with unexplained RPL (up to 30%) compared&#xD;
      to 1% to 10% of control subjects with odds ratios ranging from 2 to 5 (Press et al. 2002).&#xD;
      Likewise, other thrombophilic risk factors including factor II G20210A, hyperhomocysteinemia,&#xD;
      protein C, protein S and antithrombin deficiencies have also been associated with RPL (Sanson&#xD;
      1996; Brenner 1999).&#xD;
&#xD;
      A meta-analysis of Rey et al. (Rey 2003) including 31 case control, cohort and&#xD;
      cross-sectional studies, showed an association between thrombophilia and fetal loss, though&#xD;
      the magnitude varies according to type of fetal loss and type of thrombophilia.&#xD;
&#xD;
      Although most pregnancy losses occur in the first trimester, women with thrombophilia are at&#xD;
      an increased risk for pregnancy loss in the second and third trimesters. A number of studies&#xD;
      found that FVL carriers have a significantly higher risk of late pregnancy loss than early&#xD;
      first trimester loss (Sarig 2002; Meinardi 1999). One possible explanation is that late&#xD;
      pregnancy losses may reflect thrombosis of placental vessels. However, the majority of&#xD;
      pregnancy losses in women with thrombophilia still occur in the first trimester (Sarig 2002;&#xD;
      Younis 2000). The mechanisms responsible for the association of inherited thrombophilia with&#xD;
      RPL have not been fully elucidated. Pathological studies of placentas obtained from&#xD;
      gestations terminated by foetal loss reveal thrombotic changes and infarcts. These can be&#xD;
      observed at the maternal vessels in 50-90% of placentae of women with stillbirth (Gris 1999;&#xD;
      Many 2001). However, these changes can also be found in a significant proportion of women&#xD;
      with RPL without thrombophilia (Gris 1999; Martinelli 2000). Raising the possibility of yet&#xD;
      undetermined gestational prothrombotic risk factors either at fetal vessels or at maternal&#xD;
      vessels. A role for foetoplacental thrombosis has been suggested by studies demonstrating an&#xD;
      association between factor V genotype in miscarried foetuses and placental infarction.&#xD;
      However, the findings of thrombotic changes at the maternal side and the efficacy of LMWH,&#xD;
      which do not cross the placentae, in preventing foetal loss are in support with the latter.&#xD;
      Emerging data on therapy of women with inherited thrombophilia and pregnancy loss is mostly&#xD;
      uncontrolled and include small series of patients treated mainly with LMWH. The potential&#xD;
      advantages of LMWH over unfractionated heparin are higher antithrombotic ratio, meaning less&#xD;
      bleeding for better antithrombotic effect, longer half-life with a potential need for only&#xD;
      one injection per day, smaller injected volume and less heparin-induced thrombocytopenia.&#xD;
      These advantages are particularly appealing for prolonged prophylaxis throughout pregnancy&#xD;
      and the postpartum period. A recent collaborative study has demonstrated the safety of using&#xD;
      LMWH during 486 gestations (Sanson 1999). Successful outcome was reported in 83/93 (89%)&#xD;
      gestations in women with recurrent pregnancy loss and in all 28 gestations in women with&#xD;
      preeclampsia in previous pregnancy.&#xD;
&#xD;
      Since novel inherited and acquired prothrombotic abnormalities are currently under&#xD;
      investigation, clinicians often address the question of prophylaxis in women with RPL who do&#xD;
      not have a specific thrombophilic defect. The encouraging results presented above let rise&#xD;
      the clinical practise of LMWH therapy without the proved evidence in women without&#xD;
      thrombophilic disorders. To give the basis for a rational therapy this question should be&#xD;
      answered by this prospective randomized trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ongoing intact pregnancy at 24 weeks of gestation</measure>
    <time_frame>at 24 weeks of gestation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>late pregnancy complication, defined as at least one of the following: preterm delivery, placenta insufficiency, intrauterine growth retardation, preeclampsia and abruptio placentae</measure>
    <time_frame>6-8 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>foetus with structural anomalies</measure>
    <time_frame>6-8 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of dalteparin therapy (e.g. thrombocytopenia, osteoporosis, haemorrhage)</measure>
    <time_frame>6-8 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life birth</measure>
    <time_frame>6-8 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preterm delivery (&lt; 37 weeks of gestation)</measure>
    <time_frame>6-8 weeks after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Abortion, Habitual</condition>
  <arm_group>
    <arm_group_label>Multivitamin supplement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multivitamin supplement + dalteparin sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fragmin P Forte (dalteparin sodium)</intervention_name>
    <description>subcutaneous injection, once daily supported by multivitamine supplement and close monitoring</description>
    <arm_group_label>Multivitamin supplement + dalteparin sodium</arm_group_label>
    <other_name>low molecular weight heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin supplement</intervention_name>
    <description>general pregnancy support by multivitamin supplementation and close monitoring</description>
    <arm_group_label>Multivitamin supplement</arm_group_label>
    <other_name>Femibion 800 Folsäure plus Metafolin:</other_name>
    <other_name>Ascorbinsäure 110 mg</other_name>
    <other_name>Nicotinamid 15 mg</other_name>
    <other_name>alpha-Tocopherol acetat 13 mg</other_name>
    <other_name>RRR-alpha-Tocopherol Äquivalent 7.93 mg</other_name>
    <other_name>Pantothensäure 6 mg</other_name>
    <other_name>Pyridoxin 1.9 mg</other_name>
    <other_name>Riboflavin 1.6 mg</other_name>
    <other_name>Thiamin 1.2 mg</other_name>
    <other_name>olsäure 0.4 mg</other_name>
    <other_name>Biotin 0.06 mg</other_name>
    <other_name>Cyanocobalamin 0.0035 mg</other_name>
    <other_name>Calcium mefolinat</other_name>
    <other_name>Folsäure 0.4 mg</other_name>
    <other_name>Kalium iodid</other_name>
    <other_name>Iodid Ion 0.15 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single pregnancy, 5th to 8th week of gestation&#xD;
&#xD;
          -  Documented foetal heart activity in US&#xD;
&#xD;
          -  History of recurrent pregnancy loss, defined as:&#xD;
&#xD;
               -  2 or more early (&lt; 12 weeks of gestation) pregnancy losses or&#xD;
&#xD;
               -  1 or more late (&gt; 12 weeks of gestation) pregnancy loss&#xD;
&#xD;
          -  at least 18 years of age&#xD;
&#xD;
          -  Written informed consent of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous pregnancy losses caused by foetal structural or chromosomal anomalies&#xD;
&#xD;
          -  Uterine anomalies&#xD;
&#xD;
          -  Maternal infection which caused previous pregnancy loss&#xD;
&#xD;
          -  Risk group II or III according to ETHIG I risk stratification (clinical need for&#xD;
             heparin prophylaxis)&#xD;
&#xD;
          -  Acute thromboembolic event (need of heparin therapy)&#xD;
&#xD;
          -  Known hypersensitivity to any of the trial drugs or its ingredients (i.e.&#xD;
             thrombocytopenia type II caused by allergic reaction to heparin)&#xD;
&#xD;
          -  Antiphospholipid antibody syndrome&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Ongoing nicotine or drug or alcohol abuse&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Expected low compliance (e.g. by travel distance to trial site)&#xD;
&#xD;
          -  Current or recent (within 30 days prior to start of trial treatment) treatment with&#xD;
             another investigational drug or participation in another investigational trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekkehard Schleussner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Jena, Hospital for gynaecology and obstetrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinderwunschinstitut Schenk</name>
      <address>
        <city>Dobl</city>
        <zip>A-8143</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik am Universitätsklinikum &quot;Carl Gustav Carus&quot; der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Elisabeth und St. Barbara, Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Halle / Saale</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Abt. für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Landshut Achdorf</name>
      <address>
        <city>Landshut</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik der Technischen Universität München, Klinikum rechts der Isa</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für medizinische Genetik</name>
      <address>
        <city>Regensburg</city>
        <zip>93047</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Frauenklinik</name>
      <address>
        <city>Stuttgart</city>
        <zip>70374</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.geburtshilfe.uniklinikum-jena.de/ETHIG_II__Studie.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>November 15, 2006</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Ekkehard Schleussner</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent pregnancy loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Thiamine</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

